GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

被引：119

作者：

Brichard, Vincent G. ^{[1
]}

Lejeune, Diane ^{[1
]}

机构：

[1] GlaxoSmithKline Biol, Canc Immunotherapeut R&D, B-1330 Rixensart, Belgium

来源：

VACCINE | 2007年 / 25卷

关键词：

cancer; immunotherapy; antigens; MAGE-A3;

D O I：

10.1016/j.vaccine.2007.06.038

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

From the first evidence that the immune system could recognize tumors, different types of tumor antigens have been identified and deeply characterized. Several different approaches aimed at targeting these antigens have already been the subject of clinical studies. In this field, the GSK Biologicals' approach relying on recombinant proteins combined with an immunological Adjuvant System in a specific clinical setting, has entertained hopes of developing a new class of well tolerated anti-cancer therapy. This methodology led to promising advances with MAGE-A3 immunotherapy in NSCLC and has the potential to be applied to all tumor types. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：B61 / B71

页数：11

共 93 条

[1] Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients [J].

Atanackovic, D ;

Altorki, NK ;

Stockert, E ;

Williamson, B ;

Jungbluth, AA ;

Ritter, E ;

Santiago, D ;

Ferrara, CA ;

Matsuo, M ;

Selvakumar, A ;

Dupont, B ;

Chen, YT ;

Hoffman, EW ;

Ritter, G ;

Old, LJ ;

Gnjatic, S .

JOURNAL OF IMMUNOLOGY, 2004, 172 (05) :3289-3296

[2]

Banchereau J, 2001, CANCER RES, V61, P6451

[3] Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon [J].

Banchereau, J ;

Ueno, H ;

Dhodapkar, M ;

Connolly, J ;

Finholt, JP ;

Klechevsky, E ;

Blanck, JP ;

Johnston, DA ;

Palucka, AK ;

Fay, J .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (05) :505-516

[4] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[5] Interferon-alpha in tumor immunity and immunotherapy [J].

Belardelli, F ;

Ferrantini, M ;

Proietti, E ;

Kirkwood, JM .

CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :119-134

[6] Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study [J].

Bernhardt, S. L. ;

Gjertsen, M. K. ;

Trachsel, S. ;

Moller, M. ;

Eriksen, J. A. ;

Meo, M. ;

Buanes, T. ;

Gaudernack, G. .

BRITISH JOURNAL OF CANCER, 2006, 95 (11) :1474-1482

[7] BAGE - A NEW GENE ENCODING AN ANTIGEN RECOGNIZED ON HUMAN MELANOMAS BY CYTOLYTIC T-LYMPHOCYTES [J].

BOEL, P ;

WILDMANN, C ;

SENSI, ML ;

BRASSEUR, R ;

RENAULD, JC ;

COULIE, P ;

BOON, T ;

VANDERBRUGGEN, P .

IMMUNITY, 1995, 2 (02) :167-175

[8] Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression - Potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma [J].

Bolli, M ;

Kocher, T ;

Adamina, M ;

Guller, U ;

Dalquen, P ;

Haas, P ;

Mirlacher, M ;

Gambazzi, F ;

Harder, F ;

Heberer, M ;

Sauter, G ;

Spagnoli, GC .

ANNALS OF SURGERY, 2002, 236 (06) :785-793

[9] Human tumor antigens recognized by T lymphocytes [J].

Boon, T ;

vanderBruggen, P .

JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :725-729

[10]

Boon T, 1994, Important Adv Oncol, P53

← 1 2 3 4 5 6 7 8 9 10 →